Provectus Pharmaceuticals Inc. to Present Additional Results in 80 Patient International Multicenter Phase 2 Clinical Trial in Metastatic Melanoma at European Cancer Congress 2013
Published: Sep 12, 2013
Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that analysis of data from its completed Phase 2 study of intralesional PV-10 in metastatic melanoma will be presented at the upcoming European Cancer Congress (ECCO 17- ESMO-38 - ESTRO 32), taking place September 27 through October 1, 2013 in Amsterdam, The Netherlands.
Help employers find you! Check out all the jobs and post your resume.